Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis

Summary

The factor V Leiden mutation (FVL), associated with reduced sensitivity to activated Protein C (APC), is a risk factor for venous thromboembolism (VTE) and displays a strong interaction with oral contraceptives (OC). The aim of this study was to evaluate the risk of VTE in OC users with reduced APC sensitivity unrelated to the FVL. APC sensitivity was measured by an original aPTT-based test (without sample pre-dilution in factor V-deficient plasma) in 195 women who suffered from VTE in reproductive age and in 487 healthy women with results being expressed as normalized ratio. Subjects with currently known clinically relevant thrombophilic alterations were excluded. APC normalized ratios were stratified into quartiles. The adjusted ORs of subjects in the lower quartile (≤0.90) was 2.46 (95%CI: 1.02–5.95). Of the 195 patients, 89 had suffered VTE during OC. The 181 healthy women who had used OC for at least 6 months in the two year period before presentation but who had stopped OC at least 3 months before blood sampling were considered OC users. The risk of VTE in subjects using OC with APC normalized ratio in the lower quartile was increased 4.9-fold (95% CI: 1.92–12.6). In conclusion, our results showed that altered APC resistance in women not carrying the FVL significantly increased the VTE risk, albeit to a lesser extent than in women also carrying the FVL. Our data also showed that OC use in women with altered APC resistance further increased the risk of VTE in a way that exceeded the additive expectation.

Keywords

Activated protein C resistance - oral contraceptives - deep vein thrombosis - risk factors

• References

• 1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein-C prediction of a cofactor to activated protein-C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
• 2 Bertina RM, Koeleman BPC, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 3 Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance properties of factor V isolated from an individual with homozygosity for the Arg(506) to Gln mutation in the factor V gene. Biochem J 1996; 313: 467-72.
• 4 Heeb MJ, Kojima Y, Greengard JS. et al. Activated protein C resistance: molecular mechanisms based on studies using purified Gln(506)-factor V. Blood 1995; 85: 3405-11.
• 5 Nicolaes GAF, Tans G, Thomassen MCLGD. et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va(R506Q) by activated protein C. J Biol Chem 1995; 270: 21158-66.
• 6 Rosendaal FR, Koster T, Vandenbroucke JP. et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
• 7 Ridker PM, Hennekens CH, Lindpainter K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
• 8 Chan WP, Lee CK, Kwong YL. et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
• 9 Williamson D, Brown K, Luddington R. et al. Factor V Cambridge: a new mutation (Arg (306) → Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
• 10 Bernardi F, Faioni EM, Castoldi E. et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
• 11 Zoller B, Svensson PJ, He XH. et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
• 12 Cumming AM, Tait RC, Fildes S. et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-7.
• 13 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM. et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593-6.
• 14 Henkens CMA, Bom VJJ, Seinen AJ. et al. Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
• 15 Jick H, Jick SS, Gurewich V. et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
• 16 Olivieri O, Friso S, Manzato F. et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
• 17 Spitzer WO, Lewis MA, Heinemann LAJ. et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-8.
• 18 Rosing J, Middeldorp S, Curvers J. et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
• 19 Svensson PJ, Zoller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
• 20 Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 797-8.
• 21 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996; 07: 761-5.
• 22 Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
• 23 de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
• 24 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
• 25 Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. et al. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997; 78: 327-33.
• 26 Vandenbroucke JP, Koster T, Briet E. et al. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
• 27 Aznar J, Vaya A, Estelles A. et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000; 85: 1271-6.
• 28 Legnani C, Palareti G, Guazzaloca G. et al. Venous thromboembolism in young women: role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2001; 23: 984-90.
• 29 Legnani C, Cosmi B, Valdrè L. et al. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 2003; 01: 112-7.
• 30 Legnani C, Cosmi B, Cini M. et al. High plasma levels of Factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol (submitted).
• 31 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.